EICHOR
● Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC) · Sponsor: Amgen
About this study
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Talk to the study team
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
Locations (10)
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| United States Oncology Regulatory Affairs Corporate Office | Denver, Colorado, United States | Recruiting |
| US Oncology Research Investigational Products Center | Denver, Colorado, United States | Recruiting |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Sanford Oncology Clinic and Pharmacy | Sioux Falls, South Dakota, United States | Recruiting |
| Sarah Cannon Research Institute Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Next Oncology - Dallas | Irving, Texas, United States | Recruiting |
| Chris OBrien Lifehouse | Camperdown, New South Wales, Australia | Recruiting |
| Monash Medical Centre | Clayton, Victoria, Australia | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07493512